Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven Snapinn

Showing results (1-10 of 38) with videos related to

Pageof 4
Sort By:
Pharmaceutical Statistics|January 29, 2011
CommentarySteven Snapinn
Statistics in Medicine|July 1, 2017
Some remaining challenges regarding multiple endpoints in clinical trialsSteven Snapinn
Journal of Biopharmaceutical Statistics|February 7, 2022
A shrinkage estimator for subgroup analysis without the exchangeability assumptionSteven Snapinn
Statistics in Medicine|April 27, 2011
On the clinical meaningfulness of a treatment's effect on a time-to-event variableSteven Snapinn, Qi Jiang
Journal of Biopharmaceutical Statistics|June 22, 2013
Pure and hybrid causal effects on variables associated with an incident eventQi Jiang, Steven Snapinn
Therapeutic Innovation & Regulatory Science|September 21, 2018
Remaining Challenges in Assessing Non-InferioritySteven Snapinn, Qi Jiang
Pharmaceutical Statistics|September 30, 2011
Indirect comparisons in the comparative efficacy and non-inferiority settingsSteven Snapinn, Qi Jiang
Pharmaceutical Statistics|December 24, 2009
Analysis of multiple endpoints in clinical trials: it's time for the designations of primary, secondary and tertiary to goSteven Snapinn, Qi Jiang
Statistics in Medicine|October 5, 2007
Preservation of effect and the regulatory approval of new treatments on the basis of non-inferiority trialsSteven Snapinn, Qi Jiang
Statistics in Medicine|October 5, 2007
Controlling the type 1 error rate in non-inferiority trialsSteven Snapinn, Qi Jiang
Pageof 4

Showing results (1-10 of 38) with videos related to

Sort By:
Pageof 4
Pharmaceutical Statistics|January 29, 2011
CommentarySteven Snapinn
Statistics in Medicine|July 1, 2017
Some remaining challenges regarding multiple endpoints in clinical trialsSteven Snapinn
Journal of Biopharmaceutical Statistics|February 7, 2022
A shrinkage estimator for subgroup analysis without the exchangeability assumptionSteven Snapinn
Statistics in Medicine|April 27, 2011
On the clinical meaningfulness of a treatment's effect on a time-to-event variableSteven Snapinn, Qi Jiang
Journal of Biopharmaceutical Statistics|June 22, 2013
Pure and hybrid causal effects on variables associated with an incident eventQi Jiang, Steven Snapinn
Therapeutic Innovation & Regulatory Science|September 21, 2018
Remaining Challenges in Assessing Non-InferioritySteven Snapinn, Qi Jiang
Pharmaceutical Statistics|September 30, 2011
Indirect comparisons in the comparative efficacy and non-inferiority settingsSteven Snapinn, Qi Jiang
Pharmaceutical Statistics|December 24, 2009
Analysis of multiple endpoints in clinical trials: it's time for the designations of primary, secondary and tertiary to goSteven Snapinn, Qi Jiang
Statistics in Medicine|October 5, 2007
Preservation of effect and the regulatory approval of new treatments on the basis of non-inferiority trialsSteven Snapinn, Qi Jiang
Statistics in Medicine|October 5, 2007
Controlling the type 1 error rate in non-inferiority trialsSteven Snapinn, Qi Jiang
Pageof 4